This is an aggregated industry headline. Read the full story at Endpoints News →
#AACR26 preview: Revolution Medicines, the RAS bonanza and China ADC standouts
The oncology field is buzzing after a landmark readout from Revolution Medicines, known colloquially as RevMed, showed that a targeted "pan-RAS" drug doubled the survival time for patients whose pancreatic cancer has returned or stopped ...
By Endpoints News
· Apr 17, 2026
· via Endpoints News
Image: Endpoints News
Tags
theweekformat:headlineheadlineEndpoints News
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from The Week
All The Week →
The WeekFiercePharma ↗
For Meghan O'Hora, pharma marketing isn't about patients. It's about people and making real connections that h…
The WeekFierceBiotech ↗
Anti-aging startup NewLimit is back with a fresh fundraise of $435 million after landing on its first clinic-r…
The WeekBriefing
The agency’s Complete Response Letter delays CTx‑1301, the biotech’s first commercial hopeful, over CMC issues…